PAST, PRESENT AND FUTURE/media/Files/S/Senseon... · FOR INVESTORS ONLY | Guggenheim MedTech Disruptors Summit 2019 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking

FOR INVESTORS ONLY | Guggenhe im MedTech Disruptors Summit 2019

PAST, PRESENTAND FUTURE

Guggenheim MedTech Disruptors Summit

May 29 2019

FOR INVESTORS ONLY | Guggenhe im MedTech Disruptors Summit 2019 2

FORWARD-LOOKINGSTATEMENTS

This presentation contains forward-looking statements that are not purely historical regarding

Senseonics’ or its management’s intentions, beliefs, expectations and strategies for the future.

All forward-looking statements and reasons why results might differ included in this presentation

are made as of the date of this presentation, based on information currently available to

Senseonics, deal with future events, are subject to various risks and uncertainties, and actual

results could differ materially from those anticipated in those forward-looking statements.

The risks and uncertainties that may cause actual results to differ materially from Senseonics’

current expectations are more fully described in Senseonics’ annual report on Form 10-K for

the period ended December 31, 2017, as filed with the Securities and Exchange Commission on

March 13, 2018, its most recent quarterly report on Form 10-Q for the period ended September

30, 2018, as filed with the Securities and Exchange Commission on November 8, 2018, and its

other reports, each as filed with the Securities and Exchange Commission. Senseonics assumes

no obligation to update any such forward-looking statement after the date of this report or to

conform these forward-looking statements to actual results.


SENSEONICS PAST:Almost 20 years to develop the technology, 4 years of pivotal studies to gain US and OUS approval

50% YOY

**Application to expand Eversense indication as a therapeutic CGM;

replace fingerstick blood glucose measurement. Note: as with all transmitters,

the Eversense Smart Transmitter must be removed and stored outside

the procedure room. † Pending FDA approval.

*Now, under most circumstances and on most MRI machines, the Eversense

Smart Sensor need not be removed before an MRI, reducing concerns for

patients and doctors alike.

Founded Patented first

fluorescent

optical sensor

First

successful

human safety

trial for the

sensor

1 to 6-month

sensor

feasibility

established

System

Validation

PRECISE

demonstrated

safety &

effectiveness

of Eversense®

European

pivotal trial

completed

CE marking

for Eversense®

CGM

(90-day system)

PRECISE II

demonstrated

safety &

effectiveness of

Eversense®

CE marking for

Eversense® CGM

(180-day system)

1996 1997 2009 2010 2013 2015 2016 2017


SENSEONICS PRESENT:Almost 20 years to develop the technology, 4 years of pivotal studies to gain US and OUS approval

50% YOY

**Application to expand Eversense indication as a therapeutic CGM;

replace fingerstick blood glucose measurement. Note: as with all transmitters,

the Eversense Smart Transmitter must be removed and stored outside

the procedure room. † Pending FDA approval.

*Now, under most circumstances and on most MRI machines, the Eversense

Smart Sensor need not be removed before an MRI, reducing concerns for

patients and doctors alike.

Founded Patented first

fluorescent

optical sensor

First

successful

human safety

trial for the

sensor

1 to 6-month

sensor

feasibility

established

System

Validation

PRECISE

demonstrated

safety &

effectiveness

of Eversense®

European

pivotal trial

completed

CE marking

for Eversense®

CGM

(90-day system)

PRECISE II

demonstrated

safety &

effectiveness of

Eversense®

CE marking for

Eversense® CGM

(180-day system)

1996 1997 2009 2010 2013 2015 2016 2017


OUR COUNTRIES


THE EVERSENSE® CGM SYSTEM

SENSOR

+ Fully implanted

+ Small size

+ Up to 180 days

SMART

TRANSMITTER

+ On-body vibe alerts

+ Removable/

rechargeable

+ Gentle adhesive

EVERSENSE APP+ Real-time readings

every 5 mins+ No extra receiver+ Trends, threshold and

predictive alerts

EVERSENSE NOW+ Share capability

Labeled up to 90 days (US) and 180 days (Europe).

EVERSENSE CLOUD



EVIDENCE BUILD AND EU CLINICAL PRACTICE GUIDELINES


ABSTRACTS AND PUBLICATIONS 2019-2019


ABSTRACTS AND PUBLICATIONS 2019-2019

PUBLICATIONS in ReviewLong-Term Safety of an Implantable Continuous Glucose Sensor:

A Post-Market Registry StudyDorothee Deiss, Concetta Irace, Grace Carlson, Katherine S. Tweden, Francine R. Kaufman

Real-World Data from the First US Commercial Eversense UsersPatty Sanchez, Sam Dastidar, Katherine S. Tweden, Francine R. Kaufman


VALUE OF CGM


* Top 4 CGM company estimates based upon available publicly stated guidance,

historic performance, and external CGM market models.

GCM Fastest Growing Segment*

50% YOY

$1.2$1.7

$2.0

~$3.0

2019201820172016

CGM Global Market Size

$5

$4

$3

$2

$1Rev

enue

In B

illio

ns (

$) ~$2.2BU.S. MARKET

• Improves diabetes outcomes and

facilitates diabetes management

• Provides retrospective data

• First line technology

• Integrates with pumps, pens and

algorithms

• Growth of market year on year

HOWEVER

• Still not adequate Penetration –

30-40% of Market

• High attrition rate

WHAT ARE THE UNMET NEEDS FOR

CGM?


WHERE OUR PRESENT PATIENTSARE IN THE CGM CONTINUUM –Eversense is meeting the needs of patients using other CGMs


WHAT MAKES

EVERSENSE A

CGM OF CHOICE

• Long-term

• Implanted

• On-body vibration

• Accuracy

• Flexibility

• Data management

• Safety

FOR INVESTORS ONLY | Guggenhe im MedTech Disruptors Summit 2019 12FOR INVESTORS ONLY | Guggenhe im MedTech Disruptors Summit 2019

FIRST LOOK AT US PATIENT DATAGlucometric data on the first 205 patients who completed 90 days from sensor insertion

~1/3 CGM naïve, ~80% T1D

n=205 90 day analysis

Mean Sensor Glucose mg/dL 161.76 (33.33)

Mean SD mg/dL 57.40 (14.84)

Mean CV 0.35 (0.06)

Mean GMI % 7.18 (1.16)

%SG < 54 mg/dL 1.25 (1.75)

%SG 54-70 mg/dL 2.90 (2.51)

%SG 70-180 mg/dL 62.34 (19.04)

%SG 180-250 mg/dL 21.93 (9.66)

%SG > 250 mg/dL 11.58 (12.76)

Percent Wear of Transmitter Median wear 83.74 % of time

From total population (n=205)MARD for Calibrations (27,838 pair points) 11.44 %

Number of reinsertions Reinsertion rate - ~75%

Data on file

FOR INVESTORS ONLY | Guggenhe im MedTech Disruptors Summit 2019 13FOR INVESTORS ONLY | Guggenhe im MedTech Disruptors Summit 2019

180 DAY CLINICAL TRIAL : THE PROMISE STUDY


PRODUCT STRATEGY

• Extend wear

• Reduce/near eliminate

calibrations

• Improve on-body footprint

• Pediatric indication

• Enhance partnerships and

integrate as iCGM with AP,

CSII, Pens

• Decision support

• Type 2 strategy



EVERSENSE PIPELINE (FUTURE)

Same sensor technology. Expanded opportunities.

1 2 3

365-DAY

SENSOR LIFE:

AUTONOMOUS

SENSING

ON-DEMAND:

TYPE 2

TYPE 1:

GEMINI

1x/week calibration

additional analytes

Battery integration FGM

long-term wear w/ no

transmitter

FGM +CGM

flash when desired

CGM for peace of mind


THANK YOU

Documents

PAST, PRESENT AND FUTURE/media/Files/S/Senseon... · FOR INVESTORS ONLY | Guggenheim MedTech Disruptors Summit 2019 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking